摘要
目的:比较长春碱纳米粒和长春碱水溶液对神经胶质瘤细胞BT325的生长抑制作用。方法:采用乳化聚合法制备长春碱纳米粒,应用MTT方法检测长春碱纳米粒和长春碱水溶液对神经胶质瘤细胞BT325的生长抑制率;通过倒置显微镜、透射电镜和扫描电镜观察长春碱纳米粒和长春碱水溶液对神经胶质瘤细胞BT325形态的影响。结果:长春碱浓度为5~5000μg·L^-1处理细胞48h后,长春碱纳米粒和长春碱水溶液对神经胶质瘤细胞BT325的生长抑制率分别为41%,49%,73%,83%和28%,33%,54%,60%(P〈0.05);长春碱水溶液组细胞处于凋亡早期、凋亡小体正在形成,长春碱纳米粒组细胞处于凋亡中、末期,细胞失去结构完整性。结论:长春碱水溶液和长春碱纳米粒都具有抑制神经胶质瘤细胞BT325生长的作用,但在相同剂量下,长春碱纳米粒比长春碱水溶液抑瘤效果显著。
Objective: To compare antiproliferation effects of vinblastine nanopraticles and vinblastine water solution in human glioma cell lines BT325. Method: Vinblastine nanoparticles were prepared by emulsion polymerization process and using dextran as a stabilizing agent. It was characterized by means of morphology, size, drug entrapment efficiency and loading efficiency. Human glioma cell lines BT325 were treated with different concentrations of vinblastine nanoparticles and vinblastine water solution for 48 h, Antiproliferation effect was measured by MTr method. Morphological changes were observed by inverted microscope, transmission electron microscope and scanning electron microscope. Result: Mean diameter of VLB-PBCA-NP was about 74.4 nm, and drug entrapment efficiency and loading efficiency was 78.47% and 39. 24%, respectively. Cell growth inhibition rate of vinblastine nanoparticles group and vinblastine water solution group in a concentration range (5-5 000 g·L^-1 ) for 48 h was 41%, 49%, 73%, 83% and 28%, 33%, 54%, 60% respectively. Entrapment of VLB in NPS may distinctly degrade absorbency as compared to free drugs. Glioma cell BT325 which treated with VLB water solution were initial stage of apoptosis, and apoptosis body were forming. But VLB NPS-treated BT325 cells were intermediate or end stage, and missed structure integrality. Conclusion: VLB-PBCA-NP and VLB water Solution could inhibit the growth of human glioma cell lines BT325, and VLB nanoparticles have stronger inhibition effect compared with VLB water solution in the same dose. PBCA may be effective as promising carrier for the transport of vinblastine into the glioma cells.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2008年第20期2365-2369,共5页
China Journal of Chinese Materia Medica
基金
国家科技支撑计划(2006BAD04A11)